Compare SEAT & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEAT | TENX |
|---|---|---|
| Founded | 2001 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.0M | 74.1M |
| IPO Year | 2021 | 2001 |
| Metric | SEAT | TENX |
|---|---|---|
| Price | $2.72 | $1.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | $11.68 | ★ $12.56 |
| AVG Volume (30 Days) | 71.4K | ★ 2.2M |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.74 | $1.31 |
| 52 Week High | $13.87 | $19.40 |
| Indicator | SEAT | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 25.52 | 40.16 |
| Support Level | N/A | $1.34 |
| Resistance Level | $7.68 | $2.00 |
| Average True Range (ATR) | 0.24 | 0.12 |
| MACD | 0.06 | 0.09 |
| Stochastic Oscillator | 0.00 | 57.48 |
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry, providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada, and Japan. It operates in two segments: Marketplace, which generates maximum revenue, and Resale. The Marketplace segment acts as an intermediary between ticket buyers, sellers, and partners, earning revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. The Resale segment acquires tickets to resell on secondary ticket marketplaces, including its own, and offers internal research and development support for Skybox.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.